Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Bristol-Myers Squibb Co. (NYSE:BMY) and partner Pfizer Inc. (NYSE:PFE) said twice-daily oral Eliquis apixaban for six months met the primary endpoint of non-inferiority to conventional therapy consisting of
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury